RecruitingPhase 4NCT03826524

Epinephrine Dose: Optimal Versus Standard Evaluation Trial

Studying Hereditary persistence of fetal hemoglobin-sickle cell disease syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Unity Health Toronto
Principal Investigator
Paul Dorian, MD, MSc
Unity Health Toronto
Intervention
Epinephrine(drug)
Enrollment
3790 target
Eligibility
18 years · All sexes
Timeline
20232028

Study locations (8)

Collaborators

Canadian Institutes of Health Research (CIHR) · Pfizer

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03826524 on ClinicalTrials.gov

Other trials for Hereditary persistence of fetal hemoglobin-sickle cell disease syndrome

Additional recruiting or active studies for the same condition.

See all trials for Hereditary persistence of fetal hemoglobin-sickle cell disease syndrome

← Back to all trials